Ongoing Assessments & Recent Research.
Easy access to our work
Alzheimer’s Disease
Jul 2021Asthma
Nov 2021Atopic Dermatitis
Jul 2021Diabetes: Type 2
Jan 2022Hereditary Angioedema
Aug 2021Hypertrophic Cardiomyopathy
Oct 2021Myasthenia Gravis
Sep 2021Featured News & Insights.
Learn about our latest work.
ICER Publishes Final Evidence Report and Policy Recommendations on Aducanumab for Alzheimer’s Disease
Independent appraisal committee unanimously determined the evidence is not adequate to demonstrate that aducanumab provides a net health benefit.
08/05/2021ICER Releases Draft Evidence Report on Therapies for Myasthenia Gravis
Public comment period now open until August 18, 2021; Requests to make oral comment during public meeting also being accepted.
07/22/2021ICER Publishes Evidence Report on Therapies for Atopic Dermatitis
Evidence demonstrates the JAK inhibitors abrocitinib and upadacitinib are effective treatments for atopic dermatitis, but safety concerns about drugs in this class remain; the JAK inhibitor baricitinib and the emerging IL-13 inhibitor tralokinumab appear unlikely to be more efficacious than dupilumab, a treatment which has demonstrated long-term safety.
07/09/2021The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $300 million
Engaged with over 300 patient groups and patient reps
In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model
Current
Policy Papers.
Easy access to our ongoing policy papers
Unsupported Price Increases
Out of 10 identified drugs that had substantial 2019 price increases on top of already high current spending, seven were not supported by new clinical evidence; the net price increases on these seven drugs alone cost Americans an additional $1.2 billion in annual drug spend.
Strengthening the FDA’s Accelerated Approval Pathway
This paper aims to create a clearer understanding of both the opportunities and challenges inherent in the FDA’s accelerated approval pathway (AAP), and to present an analysis of the potential risks and benefits of a range of reform options that policymakers may consider in efforts to strengthen the AAP moving forward.
Cornerstones of ‘Fair’ Drug Coverage
Informed by expert input from patient groups, clinician specialty societies, payers, and life science companies, this white paper provides recommendations for appropriate design and implementation of policies that determine patient access to prescription drugs.
Latest
Developments.
We’re hiring! Click here to see our full time job listings.
Learn more about how the patient perspective influences ICER’s work, and learn how you can be involved.
Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.